Cargando…

Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究

OBJECTIVE: To explore the role of cell division cycle protein 37 (Cdc37) mediating bortezomib (BTZ) resistance in multiple myeloma (MM) via the regulation of autophagy activity to provide a novel strategy for MM therapy. METHODS: The expressions of Cdc37 and LC3b were investigated in BTZ-resistant M...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449775/
https://www.ncbi.nlm.nih.gov/pubmed/32810966
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.07.009
_version_ 1783574687115116544
collection PubMed
description OBJECTIVE: To explore the role of cell division cycle protein 37 (Cdc37) mediating bortezomib (BTZ) resistance in multiple myeloma (MM) via the regulation of autophagy activity to provide a novel strategy for MM therapy. METHODS: The expressions of Cdc37 and LC3b were investigated in BTZ-resistant MM cell line ANBL-6.BR using quantitative real-time PCR (qRT-PCR) and western blot (WB) analysis. Cdc37 was upregulated in ANBL-6.BR cells owing to lentivirus transfection. The LC3b expression was detected with WB, and BTZ-induced apoptosis was explored using flow cytometry. Cdc37 was then down-regulated by shRNA in the MM cell line NCI-H929. Sensitivity of BTZ was evaluated using CCK-8 analysis. WB analysis was performed to check the expression of the AKT/mTOR pathway and autophagy-associated proteins. The sensitivity of NCI-H929 cells to BTZ in the presence of autophagy inhibitor chloroquine (CQ) was analyzed using flow cytometry. RESULTS: Cdc37 was down-regulated, while autophagy-associated gene LC3b was upregulated in BTZ-resistant cell line ANBL-6.BR. Up-regulated Cdc37 in ANBL-6.BR cells could inhibit LC3b expression and increase the sensitivity of MM to BTZ. Suppressing Cdc37 expression in MM cell line NCI-H929 induced BTZ resistance and autophagy activation, while CQ could rescue BTZ resistance caused by Cdc37 inhibition. CONCLUSION: Cdc37 may participate in BTZ resistance in MM via the regulation of autophagy activity.
format Online
Article
Text
id pubmed-7449775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-74497752020-08-27 Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the role of cell division cycle protein 37 (Cdc37) mediating bortezomib (BTZ) resistance in multiple myeloma (MM) via the regulation of autophagy activity to provide a novel strategy for MM therapy. METHODS: The expressions of Cdc37 and LC3b were investigated in BTZ-resistant MM cell line ANBL-6.BR using quantitative real-time PCR (qRT-PCR) and western blot (WB) analysis. Cdc37 was upregulated in ANBL-6.BR cells owing to lentivirus transfection. The LC3b expression was detected with WB, and BTZ-induced apoptosis was explored using flow cytometry. Cdc37 was then down-regulated by shRNA in the MM cell line NCI-H929. Sensitivity of BTZ was evaluated using CCK-8 analysis. WB analysis was performed to check the expression of the AKT/mTOR pathway and autophagy-associated proteins. The sensitivity of NCI-H929 cells to BTZ in the presence of autophagy inhibitor chloroquine (CQ) was analyzed using flow cytometry. RESULTS: Cdc37 was down-regulated, while autophagy-associated gene LC3b was upregulated in BTZ-resistant cell line ANBL-6.BR. Up-regulated Cdc37 in ANBL-6.BR cells could inhibit LC3b expression and increase the sensitivity of MM to BTZ. Suppressing Cdc37 expression in MM cell line NCI-H929 induced BTZ resistance and autophagy activation, while CQ could rescue BTZ resistance caused by Cdc37 inhibition. CONCLUSION: Cdc37 may participate in BTZ resistance in MM via the regulation of autophagy activity. Editorial office of Chinese Journal of Hematology 2020-07 /pmc/articles/PMC7449775/ /pubmed/32810966 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.07.009 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
title Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
title_full Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
title_fullStr Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
title_full_unstemmed Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
title_short Cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
title_sort cdc37 调控细胞自噬参与骨髓瘤细胞对硼替佐米耐药的研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449775/
https://www.ncbi.nlm.nih.gov/pubmed/32810966
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.07.009
work_keys_str_mv AT cdc37diàokòngxìbāozìshìcānyǔgǔsuǐliúxìbāoduìpéngtìzuǒmǐnàiyàodeyánjiū
AT cdc37diàokòngxìbāozìshìcānyǔgǔsuǐliúxìbāoduìpéngtìzuǒmǐnàiyàodeyánjiū
AT cdc37diàokòngxìbāozìshìcānyǔgǔsuǐliúxìbāoduìpéngtìzuǒmǐnàiyàodeyánjiū
AT cdc37diàokòngxìbāozìshìcānyǔgǔsuǐliúxìbāoduìpéngtìzuǒmǐnàiyàodeyánjiū
AT cdc37diàokòngxìbāozìshìcānyǔgǔsuǐliúxìbāoduìpéngtìzuǒmǐnàiyàodeyánjiū